A Scientific Rationale for Using Cystic Fibrosis Transmembrane Conductance Regulator Therapeutics in COVID-19 Patients.

Front Physiol · 2020 · PMC7672116 · PMID 33250777

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

In lieu of interfering with the production of inflammatory mediators and/or interfering with specific inflammatory entities, there may be significant opportunities to improve outcomes in COVID-19 patients by modulating important downstream effectors of these inflammatory signals.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.